Hepatic Stellate Cell: A Potential Target for Hepatocellular Carcinoma

Author(s): Mengna Wu, Huajie Miao, Rong Fu, Jie Zhang*, Wenjie Zheng*

Journal Name: Current Molecular Pharmacology

Volume 13 , Issue 4 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Liver cancer is a leading cause of cancer-related death worldwide, in which hepatocellular carcinoma (HCC) accounts for the majority. Despite the progression in treatment, the prognosis remains extremely poor for HCC patients. The mechanisms of hepatocarcinogenesis are complex, of which fibrosis is acknowledged as the pre-cancerous stage of HCC. Approximately, 80-90% of HCC develops in the fibrotic or cirrhotic livers. Hepatic stellate cells (HSCs), the main effector cells of liver fibrosis, could secret various biological contents to maintain the liver inflammation. By decades, HSCs are increasingly correlated with HCC in the tumor microenvironment.

In this review, we summarized the underlying mechanisms that HSCs participated in the genesis and progression of HCC. HSCs secrete various bioactive contents and regulate tumor-related pathways, subsequently contribute to metastasis, angiogenesis, immunosuppression, chemoresistance and cancer stemness. The study indicates that HSC plays vital roles in HCC progression, suggesting it as a promising therapeutic target for HCC treatment.

Keywords: Hepatocellular carcinoma, fibrosis, hepatic stellate cell, molecular targets, therapeutics, biomarkers.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 4
Year: 2020
Page: [261 - 272]
Pages: 12
DOI: 10.2174/1874467213666200224102820
Price: $65

Article Metrics

PDF: 33